24 September 2026
Latham & Watkins Advises on Vaderis Therapeutics’ US$152 Million Series B Financing
Advising firms
Deal team
16 lawyers named| Lawyer | Firm | Seniority | Practice | Office |
|---|---|---|---|---|
| Saad Khanani Lead | Latham & Watkins LLP | Partner | corporate | Bay Area |
| Jay Trewn | Latham & Watkins LLP | Associate | corporate | Not stated |
| Camille N'Diaye-Muller | Latham & Watkins LLP | Associate | corporate | Not stated |
| Heather Deixler | Latham & Watkins LLP | Partner | data privacy and cybersecurity | Bay Area |
| Calum Docherty | Latham & Watkins LLP | Partner | data privacy and cybersecurity | London |
| Chad Leiper | Latham & Watkins LLP | Associate | data privacy and cybersecurity | Not stated |
| Clarence Cheong | Latham & Watkins LLP | Associate | data privacy and cybersecurity | Not stated |
| Robert Yeh | Latham & Watkins LLP | Counsel | intellectual property | San Diego |
| Patrick Chew | Latham & Watkins LLP | Associate | intellectual property | Not stated |
| Eveline Van Keymeulen | Latham & Watkins LLP | Partner | life sciences regulatory | Paris/Brussels |
| Amy Speros | Latham & Watkins LLP | Counsel | life sciences regulatory | San Diego |
| Breanna Comunale | Latham & Watkins LLP | Associate | life sciences regulatory | Not stated |
| Luke Nauth | Latham & Watkins LLP | Associate | life sciences regulatory | Not stated |
| Jeanne Fabre | Latham & Watkins LLP | Associate | life sciences regulatory | Not stated |
| Grace Lee | Latham & Watkins LLP | Partner | tax | Bay Area |
| Gregory Conyers | Latham & Watkins LLP | Associate | tax | Not stated |
13 more lawyers on this deal. Register free to see the full deal team, with seniority, practice and office.
REGISTER FREE SIGN INWant co-counsel patterns, repeat clients and alerts when these firms land their next deal? Get Pro.
Stated terms
- Stated value
- USD 152m (US$152 million)
- What the figure measures
- Total transaction value
- Client
- Life Sciences at Goldman Sachs AlternativesInvestor
- Counterparties
- Vaderis Therapeutics (Issuer)
TCGX (Investor)